- Company
- Two types of JAK inhibitors start a full-scale competition
- by Eo, Yun-Ho Jul 26, 2023 05:40am
- The competition between two types of JAK inhibitors in the field of juvenile atopic dermatitis has begun in earnest. Following AbbVie Korea's Rinvoq last April, Pfizer Korea's Cibinqo was covered by insurance for the indication of atopic dermatitis in children and adolescents from this month (July). Cibinqo stopped the reimbursement proce
- Policy
- Yuhan’s low-dose atorvastatin combo receives reimb
- by Lee, Tak-Sun Jul 25, 2023 05:46am
- Just as Hanmi Pharm preoccupied the market with its low-dose (2.5mg) rosuvastatin, Yuhan Corp has its hopes for its low-dose (5mg) atorvastatin to do the same. The companies’ strategy is to reduce the risk of side effects while maintaining efficacy with low-dose statins. According to industry sources, Yuhan Corp’s ‘Atovamibe Tab 10/5mg
- Company
- Decreased drug price and inclusion of impurities in Januvia
- by Jung, Sae-Im Jul 25, 2023 05:46am
- Nitrosamine impurities management hidden ambush... The standard will be significantly strengthened. The diabetes treatment 'Januvia series', for which sales rights were recently transferred to Chong Kun Dang, is experiencing sluggishness in the prescription market. Following last year's drug price cut, the company suffered voluntary withdrawals
- Policy
- Be aware of interstitial renal tubulitis when taking Vimovo
- by Lee, Hye-Kyung Jul 25, 2023 05:45am
- When taking anti-inflammatory drugs containing Esomeprazole and Naproxen, care must be taken to prevent the occurrence of interstitial renal tubulitis. The Ministry of Food and Drug Safety recently prepared a change (draft) for permission based on the results of a review of safety information on formulations containing 'esomeprazole and naproxen
- Company
- 'Paxlovid reduces the risk of deaths in high-risk groups'
- by Jung, Sae-Im Jul 25, 2023 05:45am
- ‘Paxlovid,’ the oral COVID-19 treatment used to prevent progression to severe COVID-19, has finally removed its ‘temporary’ approval tag, 1 year and 7 months after its introduction to Korea. Although the drug has now been officially approved as a new drug, it is still not being well utilized on-site. Therefore, whether the misunderstandings
- Company
- Cinqair’s quicker reimb renders reimb difficult for others
- by Eo, Yun-Ho Jul 25, 2023 05:45am
- Attention is rising on the progress of the two new asthma drugs that chose to receive reimbursement through the RSA track, unlike Cinquair. According to industry sources, GSK Korea’s ‘Nucala (mepolizumab)’ has recently been reviewed by the Health Insurance Review and Assessment Service’s Risk Sharing Agreement (RSA) subcommittee for r
- Company
- Original Forxiga’s sales strong despite generic entry
- by Kim, Jin-Gu Jul 24, 2023 05:26am
- Three months have passed since generic versions of the SGLT-2 inhibitor class diabetes treatment ‘Forxiga (dapaglifloin)’ were released en masse in Korea. Despite the release, the original product had successfully defended its lead, increasing outpatient prescriptions. The generic companies raised a combined prescription performance o
- Policy
- Reimbursement extended for 18 Factor VIII hemophilia drugs
- by Kim, Jung-Ju Jul 24, 2023 05:26am
- The reimbursement for recombinant factor VIII therapies that are used to treat hemophilia is expected to be extended soon. The government accepted the requests of related medical societies and patients and analyzed its fiscal impact, and the pharmaceutical companies with relevant products accepted the government’s request and will share the
- Opinion
- [Reporter's view] A groundbreaking policy is needed
- by Lee, Tak-Sun Jul 24, 2023 05:26am
- Controversy is in full swing over Madopar, a Parkinson's disease drug that withdrew from the Korean market early this year due to profitability issues. Patients want Madopar again, saying that the only remaining generic drug after Madopar was withdrawn has severe side effects. Furthermore, it raises the question of calculating the drug price
- Policy
- BMS makes 2nd voluntary price cut for Baraclude this year
- by Lee, Tak-Sun Jul 24, 2023 05:26am
- BMS Korea made the decision to carry out a second voluntary price cut on its flagship hepatitis B treatment ‘Baraclude’ this year. It is rare for an original drug to undergo two voluntary price cuts in one year. The industry analysis is that the company is using the price cut of its off-patent drug Baraclude as leverage to list new drug
